一過性受容体電位カチオンチャネルサブファミリーVメンバー1治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0355
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:152
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥756,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,134,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Transient Receptor Potential Cation Channel Subfamily V Member 1 – Pipeline Review, H2 2019
Summary

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) – The transient receptor potential cation channel subfamily V member 1 (TrpV1) is a protein encoded by the TRPV1 gene. It belongs to a sub-family of the transient receptor potential protein group. It mediates proton influx and may be involved in intracellular acidosis in nociceptive neurons. It is involved in mediation of inflammatory pain and hyperalgesia. It sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. It is activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. It acts as ionotropic endocannabinoid receptor with central neuromodulatory effects.

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) pipeline Target constitutes close to 43 molecules. Out of which approximately 35 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 7, 2, 16 and 6 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Dermatology, Gastrointestinal, Metabolic Disorders, Ophthalmology, Immunology, Genetic Disorders, Oncology and Respiratory which include indications Pain, Neuropathic Pain (Neuralgia), Osteoarthritis Pain, Cancer Pain, Postherpetic Neuralgia, Pruritus, Diabetic Peripheral Neuropathy, Inflammatory Pain, Keratoconjunctivitis Sicca (Dry Eye), Visceral Pain, Alzheimer’s Disease, Atherosclerosis, Atopic Dermatitis (Atopic Eczema), Autoimmune Hepatitis, Breast Cancer, Cardiomegaly, Cardiovascular Disease, Chronic Heart Failure, Cluster Headache Syndrome (Cluster Headache), Congestive Heart Failure (Heart Failure), Cough, Crohn’s Disease (Regional Enteritis), Demyelinating Diseases, Hypertension, Infantile Spasm (West Syndrome), Inflammation, Insomnia, Irritable Bowel Syndrome, Ischemia Reperfusion Injury, Morton Metatarsalgia, Myocardial Infarction, Ocular Hypertension, Ocular Pain (Eye Pain), Open-Angle Glaucoma, Parkinson’s Disease, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Post-Operative Pain, Prostate Cancer, Psoriasis, Radiculopathy, Rett Syndrome, Squamous Cell Carcinoma, Tremor, Tuberous Sclerosis and Type 2 Diabetes.

The latest report Transient Receptor Potential Cation Channel Subfamily V Member 1 – Pipeline Review, H2 2019, outlays comprehensive information on the Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
- The report reviews Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) – Overview
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) – Companies Involved in Therapeutics Development
Amorepacific Corp
AntalGenics SL
Astellas Pharma Inc
Bsense Bio Therapeutics Ltd
Centrexion Therapeutics Corp
Cmxtwenty
Concentric Analgesics Inc
DoNatur GmbH
GB Sciences Inc
GBSciences Inc
Grunenthal GmbH
GW Pharmaceuticals Plc
Interventional Analgesix Inc
Jeil Pharmaceutical Co Ltd
Medifron DBT Co Ltd
Mestex AG
Neurim Pharmaceuticals Ltd
Oblique Therapeutics AB
Pila Pharma AB
Revive Therapeutics Ltd
Scopus BioPharma Inc
Serentrix LLC
Sorrento Therapeutics Inc
Sylentis SAU
Vitality Biopharma Inc
Winston Pharmaceuticals Inc
Young BioPharma LLC
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) – Drug Profiles
AG-1529 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-8370 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Appendix

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amorepacific Corp, H2 2019
Pipeline by AntalGenics SL, H2 2019
Pipeline by Astellas Pharma Inc, H2 2019
Pipeline by Bsense Bio Therapeutics Ltd, H2 2019
Pipeline by Centrexion Therapeutics Corp, H2 2019
Pipeline by Cmxtwenty, H2 2019
Pipeline by Concentric Analgesics Inc, H2 2019
Pipeline by DoNatur GmbH, H2 2019
Pipeline by GB Sciences Inc, H2 2019
Pipeline by GBSciences Inc, H2 2019
Pipeline by Grunenthal GmbH, H2 2019
Pipeline by GW Pharmaceuticals Plc, H2 2019
Pipeline by Interventional Analgesix Inc, H2 2019
Pipeline by Jeil Pharmaceutical Co Ltd, H2 2019
Pipeline by Medifron DBT Co Ltd, H2 2019
Pipeline by Mestex AG, H2 2019
Pipeline by Neurim Pharmaceuticals Ltd, H2 2019
Pipeline by Oblique Therapeutics AB, H2 2019
Pipeline by Pila Pharma AB, H2 2019
Pipeline by Revive Therapeutics Ltd, H2 2019
Pipeline by Scopus BioPharma Inc, H2 2019
Pipeline by Serentrix LLC, H2 2019
Pipeline by Sorrento Therapeutics Inc, H2 2019
Pipeline by Sylentis SAU, H2 2019
Pipeline by Vitality Biopharma Inc, H2 2019
Pipeline by Winston Pharmaceuticals Inc, H2 2019
Pipeline by Young BioPharma LLC, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Dormant Products, H2 2019 (Contd..5), H2 2019
Discontinued Products, H2 2019
Discontinued Products, H2 2019 (Contd..1), H2 2019

【掲載企業】

Amorepacific Corp
AntalGenics SL
Astellas Pharma Inc
Bsense Bio Therapeutics Ltd
Centrexion Therapeutics Corp
Cmxtwenty
Concentric Analgesics Inc
DoNatur GmbH
GB Sciences Inc
GBSciences Inc
Grunenthal GmbH
GW Pharmaceuticals Plc
Interventional Analgesix Inc
Jeil Pharmaceutical Co Ltd
Medifron DBT Co Ltd
Mestex AG
Neurim Pharmaceuticals Ltd
Oblique Therapeutics AB
Pila Pharma AB
Revive Therapeutics Ltd
Scopus BioPharma Inc
Serentrix LLC
Sorrento Therapeutics Inc
Sylentis SAU
Vitality Biopharma Inc
Winston Pharmaceuticals Inc
Young BioPharma LLC

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[一過性受容体電位カチオンチャネルサブファミリーVメンバー1治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆